Added to YB: 2026-10-09
Pitch date: 2026-10-04
BBOT [bullish]
BridgeBio Oncology Therapeutics, Inc.
-25.13%
current return
Author Info
No bio for this author
Company Info
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Market Cap
$280.6M
Pitch Price
$3.88
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.31
P/E
-1.37
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - BridgeBio Oncology Therapeutics, Inc.
BBOT (hold): BridgeBio Oncology is a targeted-oncology spinout with its parent company’s scientific and operational footprint and a portfolio of potential precision-oncology assets, including KRAS-adjacent opportunities. The thesis depends on pipeline development and asset selection rather than an established commercial franchise; potential partners or acquirers can wait for validation or engage around a single program, limiting strategic urgency and keeping the position in the satellite tier.
Read full article (1 min)